Price
$0.72
Decreased by -7.63%
Dollar volume (20D)
145.83 K
ADR%
6.82
Earnings report date
Aug 12, 2024
Shares float
7.97 M
Shares short
435.07 K [5.46%]
Shares outstanding
10.85 M
Market cap
8.49 M
Beta
0.71
Price/earnings
N/A
20D range
0.71 1.10
50D range
0.71 1.73
200D range
0.67 3.35

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.

It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.

ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.

The company is based in Fremont, California.

ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 30, 24 -0.40
Decreased by -573.33%
-
Mar 14, 24 -0.39
Decreased by -161.20%
-
Nov 15, 23 -0.82
Decreased by -643.73%
-0.04
Decreased by -1.95 K%
Aug 14, 23 -0.68
Decreased by -1.04 K%
-0.06
Decreased by -1.04 K%
May 15, 23 -0.06
Increased by +70.00%
-0.05
Decreased by -20.00%
Mar 31, 23 -0.15
Increased by +51.61%
-0.15
Nov 14, 22 -0.11
Decreased by -57.14%
-0.12
Increased by +8.33%
Aug 15, 22 -0.06
Increased by +25.00%
-0.12
Increased by +50.00%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 1.21 K
Decreased by -99.06%
-3.93 M
Decreased by -5.25 K%
Decreased by -326.39 K%
Decreased by -569.24 K%
Dec 31, 23 2.17 K
Decreased by -99.63%
-3.11 M
Increased by +30.88%
Decreased by -143.69 K%
Decreased by -18.70 K%
Sep 30, 23 15.88 K
Decreased by -62.42%
-3.32 M
Increased by +12.15%
Decreased by -20.89 K%
Decreased by -133.77%
Jun 30, 23 6.11 K
Decreased by -98.05%
-2.26 M
Decreased by -16.24%
Decreased by -37.05 K%
Decreased by -5.85 K%
Mar 31, 23 128.27 K
Increased by +399.89%
-73.53 K
Increased by +98.79%
Decreased by -57.33%
Increased by +99.76%
Dec 31, 22 588.99 K
Increased by +1.66 K%
-4.50 M
Increased by +43.26%
Decreased by -764.17%
Decreased by -103.64%
Sep 30, 22 42.27 K
Decreased by -57.30%
-3.78 M
Decreased by -109.05%
Decreased by -8.93 K%
Decreased by -389.63%
Jun 30, 22 312.86 K
Increased by +895.07%
-1.95 M
Increased by +1.23%
Decreased by -622.43%
Increased by +90.07%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY